Maxion Therapeutics Secures $72 Million in Series A Funding
Deal News | Mar 17, 2025 | Goodwin
Maxion Therapeutics, a pioneering developer of antibody-like therapeutics known as KnotBodies, has successfully raised $72 million in a Series A funding round. This fundraising initiative was primarily led by General Catalyst, with significant contributions from new investors such as British Patient Capital, Solasta Ventures, and Eli Lilly and Company. The round also saw continued support from existing investors including LifeArc Ventures, Monograph Capital, and BGF. The financial advising for the funding initiative was provided by Goodwin's London & Cambridge Life Sciences team, with key team members including David Mardle, Elizabeth Rhodes, Heidi McNally, and George Fagan. The capital raised will support Maxion Therapeutics in advancing its innovative therapeutic platform aimed at treating ion channel and GPCR-driven diseases.
Sectors
- Biotechnology
- Healthcare
- Financial Services
Geography
- United Kingdom – Maxion Therapeutics is based in the UK and involved UK investors like British Patient Capital and BGF.
Industry
- Biotechnology – Maxion Therapeutics is part of the biotechnology industry as it develops innovative therapies using its KnotBodies platform.
- Healthcare – The company focuses on treating diseases driven by ion channels and GPCR, which places it in the healthcare sector.
- Financial Services – The article involves significant investment activities, including a Series A funding round, relevant to the financial services industry.
Financials
- $72 million – The total amount raised by Maxion Therapeutics in the Series A funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Maxion Therapeutics | Target Company | Company | Developer of KnotBodies aimed at treating ion channel and GPCR-driven diseases. |
| General Catalyst | Lead Investor | Company | A venture capital firm leading the Series A funding round for Maxion. |
| British Patient Capital | Investor | Company | A UK-based investor participating in Maxion's Series A funding. |
| Solasta Ventures | Investor | Company | A new investor in Maxion's funding round. |
| Eli Lilly and Company | Investor | Company | A global pharmaceutical company participating as a new investor. |
| LifeArc Ventures | Existing Investor | Company | A previous investor providing continued support in the Series A round. |
| Monograph Capital | Existing Investor | Company | An existing investor in Maxion Therapeutics. |
| BGF | Existing Investor | Company | A current investor based in the UK that supported the Series A funding. |
| Goodwin | Legal Advisor | Company | Legal advisors from the London & Cambridge Life Sciences team supported Maxion in the funding round. |
| David Mardle | Legal Advisor | Person | A key member of Goodwin's advisory team for Maxion. |
| Elizabeth Rhodes | Legal Advisor | Person | A member of Goodwin's team advising Maxion. |
| Heidi McNally | Legal Advisor | Person | Part of the Goodwin team advising Maxion. |
| George Fagan | Legal Advisor | Person | Involved in providing legal advice at Goodwin for Maxion. |